PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.

Abstract

<b>Purpose:</b> Leukemia stem cells (LSCs) are an important source of tyrosine kinase inhibitor resistance and disease relapse in patients with chronic myelogenous leukemia (CML). Targeting LSCs may be an attractive strategy to override this thorny problem. Given that <i>EZH2</i> was overexpressed in primary CML CD34⁺ cells, our purpose in this study was to evaluate the effects of targeting EZH2 on CML LSCs and clarify its underlying mechanism.<b>Experimental Design:</b> Human primary CML CD34⁺ cells and retrovirally <i>BCR-ABL</i>-driven CML mouse models were employed to evaluate the effects of suppression of EZH2 by <i>GSK126</i>- or <i>EZH2</i>-specific shRNA <i>in vitro</i> and <i>in vivo</i> Recruitment of EZH2 and H3K27me3 on the promoter of tumor-suppressor gene <i>PTEN</i> in CML cells was measured by chromatin immunoprecipitation assay.<b>Results:</b> Our results showed that pharmacologic inhibition of EZH2 by GSK126 not only elicited apoptosis and restricted cell growth in CML bulk leukemia cells, but also decreased LSCs in CML CD34⁺ cells while sparing those from normal bone marrow CD34⁺ cells. Suppression of EZH2 by GSK126 or specific shRNA prolonged survival of CML mice and reduced the number of LSCs in mice. <i>EZH2</i> knockdown resulted in elevation of <i>PTEN</i> and led to impaired recruitment of EZH2 and H3K27me3 on the promoter of <i>PTEN</i> gene. The effect of <i>EZH2</i> knockdown in the CML mice was at least partially reversed by <i>PTEN</i> knockdown.<b>Conclusions:</b> These findings improve the understanding of the epigenetic regulation of stemness in CML LSCs and warrant clinical trial of GSK126 in refractory patients with CML. <i>Clin Cancer Res; 24(1); 145-57. ©2017 AACR</i>.